These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Heist RS; Duda DG; Sahani DV; Ancukiewicz M; Fidias P; Sequist LV; Temel JS; Shaw AT; Pennell NA; Neal JW; Gandhi L; Lynch TJ; Engelman JA; Jain RK Proc Natl Acad Sci U S A; 2015 Feb; 112(5):1547-52. PubMed ID: 25605928 [TBL] [Abstract][Full Text] [Related]
23. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor. Kaminska J; Kowalska M; Kotowicz B; Fuksiewicz M; Glogowski M; Wojcik E; Chechlinska M; Steffen J Oncology; 2006; 70(2):115-25. PubMed ID: 16645324 [TBL] [Abstract][Full Text] [Related]
24. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Byers LA; Holsinger FC; Kies MS; William WN; El-Naggar AK; Lee JJ; Hu J; Lopez A; Tran HT; Yan S; Du Z; Ang KK; Glisson BS; Raso MG; Wistuba II; Myers JN; Hong WK; Papadimitrakopoulou V; Lippman SM; Heymach JV Mol Cancer Ther; 2010 Jun; 9(6):1755-63. PubMed ID: 20530716 [TBL] [Abstract][Full Text] [Related]
28. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Suttle AB; Ball HA; Molimard M; Hutson TE; Carpenter C; Rajagopalan D; Lin Y; Swann S; Amado R; Pandite L Br J Cancer; 2014 Nov; 111(10):1909-16. PubMed ID: 25349968 [TBL] [Abstract][Full Text] [Related]
29. Prognostic and Predictive Role of Angiogenic Markers in Non- Small Cell Lung Cancer. Keskin S; Kutluk AC; Tas F Asian Pac J Cancer Prev; 2019 Mar; 20(3):733-736. PubMed ID: 30909672 [TBL] [Abstract][Full Text] [Related]
31. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. O'Donnell PH; Karovic S; Karrison TG; Janisch L; Levine MR; Harris PJ; Polite BN; Cohen EE; Fleming GF; Ratain MJ; Maitland ML Clin Cancer Res; 2015 Nov; 21(22):5092-9. PubMed ID: 26199386 [TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Giatromanolaki A; Koukourakis MI; Kakolyris S; Turley H; O'Byrne K; Scott PA; Pezzella F; Georgoulias V; Harris AL; Gatter KC Clin Cancer Res; 1998 Dec; 4(12):3017-24. PubMed ID: 9865915 [TBL] [Abstract][Full Text] [Related]
33. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma. Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178 [TBL] [Abstract][Full Text] [Related]
34. Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma. Zurita AJ; Gagnon RC; Liu Y; Tran HT; Figlin RA; Hutson TE; D'Amelio AM; Sternberg CN; Pandite LN; Heymach JV Br J Cancer; 2017 Aug; 117(4):478-484. PubMed ID: 28683470 [TBL] [Abstract][Full Text] [Related]
35. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib. Kimura H; Kasahara K; Sekijima M; Tamura T; Nishio K Lung Cancer; 2005 Dec; 50(3):393-9. PubMed ID: 16153743 [TBL] [Abstract][Full Text] [Related]
36. Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma. Bonate PL; Suttle AB Cancer Chemother Pharmacol; 2013 Jul; 72(1):231-40. PubMed ID: 23715625 [TBL] [Abstract][Full Text] [Related]
37. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Donnem T; Al-Saad S; Al-Shibli K; Delghandi MP; Persson M; Nilsen MN; Busund LT; Bremnes RM Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6649-57. PubMed ID: 18006765 [TBL] [Abstract][Full Text] [Related]
38. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Merritt WM; Nick AM; Carroll AR; Lu C; Matsuo K; Dumble M; Jennings N; Zhang S; Lin YG; Spannuth WA; Kamat AA; Stone RL; Shahzad MM; Coleman RL; Kumar R; Sood AK Mol Cancer Ther; 2010 Apr; 9(4):985-95. PubMed ID: 20371710 [TBL] [Abstract][Full Text] [Related]
39. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas. Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826 [TBL] [Abstract][Full Text] [Related]
40. Nintedanib for the treatment of non-small-cell lung cancer. Rashdan S; Hanna N Expert Opin Pharmacother; 2014 Apr; 15(5):729-39. PubMed ID: 24597846 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]